ImmuPharma plc (LON:IMM – Get Free Report) shares were up 29.3% on Thursday . The stock traded as high as GBX 2.80 ($0.04) and last traded at GBX 2.78 ($0.04). Approximately 504,310 shares were traded during trading, a decline of 95% from the average daily volume of 10,802,349 shares. The stock had previously closed at GBX 2.15 ($0.03).
ImmuPharma Stock Performance
The stock has a market capitalization of £11.82 million, a PE ratio of -4.81 and a beta of 1.53. The stock’s 50 day moving average is GBX 3.55 and its two-hundred day moving average is GBX 2.51.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Joby Aviation: Operational Momentum vs. Market Sentiment
- 3 Warren Buffett Stocks to Buy Now
- Broadcom’s Big Outperformance Shows Strength Amid Tariff Decline
- Are Penny Stocks a Good Fit for Your Portfolio?
- Carvana: Can Turnaround Strength Outdrive Market Headwinds?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
